Meanwhile, the BSE Sensex was down 225.68 points, or 1.37% to 16,236.03.
On BSE, 2.53 lakh shares were traded in the counter as against average daily volume of 1.21 lakh shares in the past one quarter.
The stock hit a high of Rs 318 and a low of Rs 309.85 so far during the day. The stock had hit a 52-week low of Rs 273.60 on 6 September 2011. The stock had hit a record high of Rs 380.80 on 4 January 2011.
The stock has risen 9.3% in four trading sessions from Rs 288.15 on Monday, 14 November 2011, boosted by strong Q2 earnings announced by the company after trading hours on Monday, 14 November 2011.
The stock outperformed the market over the past one month till 17 November 2011, gaining 7.34% compared with the Sensex's 3.31% fall. The scrip had also outperformed the market in past one quarter, rising 7.51% as against 2.25% decline in the Sensex.
The large-cap drug maker has equity capital of Rs 160.58 crore. Face value per share is Rs 2.
Cipla's net profit rose 17.5% to Rs 308.97 crore on 9.6% growth in net sales to Rs 1731.83 crore in Q2 September 2011 over Q2 September 2010.
Cipla's sales grew on the back of double digit growth in domestic and export formulation businesses. At operating level, margins expanded by 220 basis points to 24.6% on the back of lower consumption cost due to improved realizations, reduction in input costs of certain products, coupled with the change in product mix and higher cost efficiencies due to increased utilization levels at Indore special economic zone (SEZ) facilities. As a result, there was 19% growth in operating profit to Rs 437.61 crore.
Cipla manufactures pharmaceutical products. The products of the company include anti-asthmatics, anti-cancer, anti-inflammatory, anti-depressant and other therapeutic products including animal health care products.